CJ HealthCare acquires approval of new antiemetic ‘Akynzeo’
CJ HealthCare announced on the 1st that a new antiemetic ‘Akynzeo Cap’ was approved by the Ministry of Food and Drug Safety.
With the Akynzeo’s approval, CJ HealthCare has firmed its position in the anticancer supplement market with Aloxi.
Akynzeo is a new drug containing ‘Palonosetron’ with ‘N...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
